4Paws DX, Inc

4Paws DX, Inc is a leading provider of liquid biopsy technology for early cancer detection in dogs. Their OncoK9 multi-cancer early detection (MCED) test utilizes cutting-edge genomic analysis and next-generation sequencing technology to detect genomic alterations associated with cancer. With a simple blood draw, veterinarians can provide superior care to canine patients by identifying cancer signals before the onset of clinical signs.

Each year, approximately 6 million dogs are newly diagnosed with cancer in the United States, making it the most common cause of death in adult dogs. 4Paws DX, Inc aims to change this by offering a non-invasive and efficient solution for early cancer detection in dogs. Their OncoK9 test has been clinically validated in over 1,000 dogs, demonstrating its ability to detect 30 different types of cancer. By providing veterinarians with valuable information about a dog's cancer status, 4Paws DX, Inc is helping to improve treatment options and increase the chances of long-term control or cure for canine cancer.

Generated from the website